Robeco Institutional Asset Management B.V. Buys 12,405 Shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Robeco Institutional Asset Management B.V. lifted its holdings in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) by 6.2% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 213,709 shares of the specialty pharmaceutical company's stock after purchasing an additional 12,405 shares during the quarter. Robeco Institutional Asset Management B.V. owned 0.35% of Jazz Pharmaceuticals worth $26,532,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of the business. Fuller & Thaler Asset Management Inc. increased its stake in Jazz Pharmaceuticals by 117.4% during the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 939,351 shares of the specialty pharmaceutical company's stock worth $115,681,000 after purchasing an additional 507,234 shares in the last quarter. Darwin Global Management Ltd. acquired a new position in shares of Jazz Pharmaceuticals in the fourth quarter valued at approximately $59,668,000. Dimensional Fund Advisors LP increased its position in shares of Jazz Pharmaceuticals by 18.7% during the fourth quarter. Dimensional Fund Advisors LP now owns 2,035,070 shares of the specialty pharmaceutical company's stock worth $250,619,000 after acquiring an additional 320,724 shares in the last quarter. Ameriprise Financial Inc. increased its position in shares of Jazz Pharmaceuticals by 20.9% during the fourth quarter. Ameriprise Financial Inc. now owns 1,827,658 shares of the specialty pharmaceutical company's stock worth $225,076,000 after acquiring an additional 315,608 shares in the last quarter. Finally, GMT Capital Corp raised its holdings in shares of Jazz Pharmaceuticals by 140.0% during the fourth quarter. GMT Capital Corp now owns 508,800 shares of the specialty pharmaceutical company's stock worth $62,659,000 after acquiring an additional 296,800 shares during the period. Institutional investors own 89.14% of the company's stock.

Jazz Pharmaceuticals Stock Down 0.6%

JAZZ stock traded down $0.61 during mid-day trading on Friday, reaching $106.90. The company had a trading volume of 871,418 shares, compared to its average volume of 826,247. The company has a market capitalization of $6.47 billion, a price-to-earnings ratio of 14.25, a PEG ratio of 4.61 and a beta of 0.33. Jazz Pharmaceuticals PLC has a 52 week low of $95.49 and a 52 week high of $148.06. The stock has a 50 day simple moving average of $108.63 and a two-hundred day simple moving average of $119.56. The company has a debt-to-equity ratio of 1.28, a current ratio of 3.38 and a quick ratio of 2.97.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 EPS for the quarter, missing analysts' consensus estimates of $4.65 by ($2.97). The firm had revenue of $897.84 million during the quarter, compared to analyst estimates of $984.16 million. Jazz Pharmaceuticals had a net margin of 11.86% and a return on equity of 26.62%. The business's revenue was down .5% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.68 EPS. As a group, equities analysts predict that Jazz Pharmaceuticals PLC will post 16.96 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

JAZZ has been the subject of a number of research analyst reports. Robert W. Baird reduced their target price on shares of Jazz Pharmaceuticals from $167.00 to $155.00 and set an "outperform" rating for the company in a research note on Wednesday, May 7th. Truist Financial boosted their price target on Jazz Pharmaceuticals from $220.00 to $230.00 and gave the company a "buy" rating in a report on Thursday, March 6th. Piper Sandler reaffirmed an "overweight" rating and set a $147.00 price objective (down from $176.00) on shares of Jazz Pharmaceuticals in a research report on Wednesday, May 7th. Wall Street Zen downgraded Jazz Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Thursday, May 15th. Finally, Needham & Company LLC restated a "buy" rating and issued a $202.00 target price on shares of Jazz Pharmaceuticals in a research note on Wednesday, June 11th. Two investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $184.00.

Insider Transactions at Jazz Pharmaceuticals

In related news, Director Seamus Mulligan acquired 100,000 shares of the business's stock in a transaction on Friday, May 9th. The stock was purchased at an average cost of $98.26 per share, for a total transaction of $9,826,000.00. Following the completion of the transaction, the director now directly owns 100,000 shares of the company's stock, valued at approximately $9,826,000. The trade was a ∞ increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Bruce C. Cozadd sold 1,500 shares of the business's stock in a transaction on Tuesday, April 1st. The shares were sold at an average price of $123.75, for a total value of $185,625.00. Following the completion of the sale, the chief executive officer now owns 440,307 shares of the company's stock, valued at $54,487,991.25. This trade represents a 0.34% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 3,000 shares of company stock worth $355,925. 4.30% of the stock is owned by company insiders.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.